Results 231 to 240 of about 222,357 (321)

Cuproplasia and cuproptosis, two sides of the coin

open access: yesCancer Communications, EarlyView.
Abstract Copper is an essential micronutrient in the human body, mainly acting as a crucial cofactor required for a wide range of physiological processes across nearly all cell types. Recent advances revealed that tumor cells seize copper to fulfill their rapid proliferation, metastasis, immune evasion, and so on by reprogramming the copper regulatory ...
Kaizhong Lu   +4 more
wiley   +1 more source

Breaking barriers: Smart vaccine platforms for cancer immunomodulation

open access: yesCancer Communications, EarlyView.
Abstract Despite significant advancements in cancer treatment, current therapies often fail to completely eradicate malignant cells. This shortfall underscores the urgent need to explore alternative approaches such as cancer vaccines. Leveraging the immune system's natural ability to target and kill cancer cells holds great therapeutic potential ...
Mohammad Mahmoudi Gomari   +11 more
wiley   +1 more source

Nano-drug delivery systems integrated with low radiation doses for enhanced therapeutic efficacy in cancer treatment.

open access: yesWorld J Clin Cases
Pontoriero A   +9 more
europepmc   +1 more source

Glioblastoma Cells Express and Secrete Alternatively Spliced Transcripts of Coagulation Factor X. [PDF]

open access: yesBiomedicines
Li X   +17 more
europepmc   +1 more source

Copper in cancer: friend or foe? Metabolism, dysregulation, and therapeutic opportunities

open access: yesCancer Communications, EarlyView.
Abstract Copper, one of the essential nutrients for the human body, acts as an electron relay in multiple pathways due to its redox properties. Both deficiencies and excesses of copper lead to cellular fragility. Therefore, it can manifest pro‐ and anti‐cancer properties in tumors. Therefore, it is crucial to clarify the copper activity within the cell.
Dan Shan   +13 more
wiley   +1 more source

Blocking ITGA5 potentiates the efficacy of anti‐PD‐1 therapy on glioblastoma by remodeling tumor‐associated macrophages

open access: yesCancer Communications, EarlyView.
Abstract Background Glioblastoma (GBM) is largely refractory to antibodies against programmed cell death 1 (anti‐PD‐1) therapy. Fully understanding the cellular heterogeneity and immune adaptations in response to anti‐PD‐1 therapy is necessary to design more effective immunotherapies for GBM.
Rongrong Zhao   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy